Health-related quality of life outcomes from botulinum toxin treatment in hemifacial spasm

作者：Weiss Daniel; Sturm Justine; Hieber Leonhard; Boertlein Axel; Mayr Ingo; Appy Matthias; Kuehnler Benedicta; Buchthal Joachim; Dippon Christian; Arnold Guy; Waechter Tobias

来源：Therapeutic Advances in Neurological Disorders, 2017, 10(4): 211-216.

DOI：10.1177/1756285616682676

• botulinum toxin
• hemifacial spasm
• quality of life

Background: Although botulinum neurotoxin (BoNT) injections may alleviate involuntary muscle contractions in hemifacial spasm substantially, it is less clear whether the motor effect would translate into improvements of health-related quality of life (HR-QoL).
Methods: In this open-label clinical observational study, we characterized outcomes on HR-QoL in terms of the EuroQol (EQ-5D-5L) from BoNT in a prospective cohort of patients with hemifacial spasm (n = 73). Additionally, we characterized appendicular motor and nonmotor signs on motor symptom improvement, depressive symptoms, pain and sleep quality. Patients were assessed at the end of a regular 3-month period from last injection (timepoint1) and 4 weeks after the reinjection of BoNT (timepoint2).
Results: Patients showed improved HR-QoL on the EQ-VAS (visual analogue scale) at timepoint2 compared with timepoint1. Moreover, we identified, that impairments in HR-QoL at timepoint1 correlated with life satisfaction and depressive symptoms, respectively. However, these associated variables did not predict the therapeutic effect. Instead, EQ-VAS at timepoint1 accounted for 34.5% of the variance of EQ-VAS improvement expressed as the difference between timepoint2 and timepoint1.
Conclusion: Our study supports HR-QoL improvements in hemifacial spasm and the value of generic HR-QoL measures to estimate therapeutic outcome. However, the findings should be considered descriptive, and future high quality trials are needed for confirmatory purposes in order to refine treatment referral in hemifacial spasm with respect to QoL.

• 出版日期2017-4